STOCK TITAN

CVRx to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call on October 26th, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
CVRx to release Q3 2023 financial results on October 26th
Positive
  • CVRx plans to release its third quarter 2023 financial and operating results after market close on October 26th, 2023.
Negative
  • None.

MINNEAPOLIS, Oct. 12, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release third quarter 2023 financial and operating results after market close on Thursday, October 26th, 2023. The Company will host a conference call to review its results at 5:30 p.m. Eastern Time the same day.

A live webcast of the investor conference call will be available online at the investor relations page of the Company’s website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1-877-704-4453 for U.S. callers, or 1-201-389-0920 for international callers, approximately ten minutes prior to the start time. 

About CVRx, Inc.

CVRx is a commercial-stage medical device company focused on the developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com. 

Investor Contact:
Mark Klausner or Mike Vallie
ICR Westwicke
443-213-0501
ir@cvrx.com 

Media Contact:
Laura O’Neill
Finn Partners
212-867-1762
laura.oneill@finnpartners.com

 


FAQ

When will CVRx release its Q3 2023 financial results?

CVRx plans to release its third quarter 2023 financial and operating results after market close on Thursday, October 26th, 2023.

What time will the conference call to review the results take place?

The conference call to review the results will take place at 5:30 p.m. Eastern Time on October 26th, 2023.

Where can I access the live webcast of the investor conference call?

The live webcast of the investor conference call will be available online at the investor relations page of CVRx's website at ir.cvrx.com.

What are the dial-in numbers for the conference call?

For U.S. callers, please dial 1-877-704-4453. For international callers, please dial 1-201-389-0920.

When should I dial in for the conference call?

Please dial in approximately ten minutes prior to the start time of the conference call.

CVRx, Inc.

NASDAQ:CVRX

CVRX Rankings

CVRX Latest News

CVRX Stock Data

314.46M
21.83M
4.4%
71.89%
8.49%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
MINNEAPOLIS